Variables | With bleeding events (n = 41) | Without bleeding events (n = 93) | Univariate analysis | Multivariate analysis† (stepwise selection method) | ||||
---|---|---|---|---|---|---|---|---|
p-value | OR (95% CI) | p-value | ||||||
n (%) | n (%) | |||||||
Age > 80 years | 17 | (41.5) | 21 | (22.6) | 0.025a)* | 2.536 (1.099–5.853) | 0.029* | |
Sex, male | 32 | (78.0) | 79 | (84.9) | 0.329a) | |||
Body mass index < 20 (kg/m2) | 11 | (26.8) | 15 | (16.1) | 0.149a) | |||
Smoking history | 30 | (73.2) | 53 | (57.0) | 0.075a) | |||
Alcohol consumption history | 18 | (45.0) | 44 | (47.3) | 0.806a) | |||
Systolic BP ≥ 140 (mmHg) | 6 | (14.6) | 21 | (22.6) | 0.291a) | |||
Diastolic BP ≥ 90 (mmHg) | 4 | (9.8) | 7 | (7.5) | 0.736b) | |||
History of surgery | 12 | (29.3) | 10 | (10.8) | 0.008a)* | 3.031 (1.141–8.055) | 0.026* | |
History of bleeding | 10 | (24.4) | 9 | (9.7) | 0.024a) | |||
History of CABG | 3 | (7.3) | 3 | (3.2) | 0.370b) | |||
Concomitant disease or medical history | ||||||||
Hypertension | 35 | (85.4) | 66 | (71.0) | 0.075a) | |||
Dyslipidemia | 26 | (63.4) | 45 | (48.4) | 0.156a) | |||
Diabetes mellitus | 15 | (36.6) | 31 | (33.3) | 0.715a) | |||
Cerebral infarction | 7 | (17.1) | 18 | (19.4) | 0.755a) | |||
Myocardial infection | 5 | (12.2) | 11 | (11.8) | 1.000b) | |||
Heart failure | 19 | (46.3) | 36 | (38.7) | 0.408a) | |||
Malignancy | 10 | (24.4) | 15 | (16.1) | 0.258a) | |||
Dialysis | 2 | (4.9) | 3 | (3.2) | 0.642b) | |||
Liver disease | 3 | (7.3) | 5 | (5.4) | 0.700b) | |||
Anemia | 14 | (34.1) | 16 | (17.2) | 0.030a)* | |||
Gastrointestinal disease | 13 | (31.7) | 17 | (18.3) | 0.086a) | |||
Peripheral arterial disease | 5 | (12.2) | 11 | (11.8) | 1.000b) | |||
PCI profile | ||||||||
Number of target lesions ≥ 2 | 15 | (36.6) | 33 | (35.5) | 0.902a) | |||
Lesion site | 0.866b) | |||||||
RCA | 10 | (24.4) | 21 | (22.6) | ||||
LMT | 1 | (2.4) | 4 | (4.3) | ||||
LAD | 22 | (53.7) | 54 | (58.1) | ||||
LCX | 8 | (19.5) | 14 | (15.1) | ||||
Chronic total occlusion | 11 | (26.8) | 22 | (23.7) | 0.694a) | |||
Multivessel disease | 28 | (68.3) | 41 | (44.1) | 0.010a)* | 2.761 (1.223–6.231) | 0.014* | |
Stent type | 0.418a) | |||||||
BMS | 9 | (22.0) | 15 | (16.1) | ||||
DES | 32 | (78.0) | 78 | (83.9) | ||||
Clinical presentation | 0.306a) | |||||||
ACS | 22 | (53.7) | 41 | (44.1) | ||||
stable CAD | 19 | (46.3) | 52 | (55.9) | ||||
Laboratory data | ||||||||
Albumin < 3.5 (g/dL) | 14 | (34.1) | 29 | (31.2) | 0.735a) | |||
White blood cell ≥ 10,000 (/µL) | 9 | (22.0) | 10 | (10.8) | 0.087a) | |||
Hemoglobin < 11 (g/dL) | 9 | (22.0) | 15 | (16.1) | 0.418a) | |||
Platelet < 10 (104/µL) | 2 | (4.9) | 1 | (1.1) | 0.222b) | |||
AST > 50 (U/L) | 13 | (31.7) | 19 | (20.4) | 0.158a) | |||
ALT > 50 (U/L) | 6 | (14.6) | 13 | (14.0) | 0.920a) | |||
eGFR (mL/min/1.73m2) | 0.086a) | |||||||
< 30 | 6 | (14.6) | 4 | (4.3) | ||||
30–45 | 7 | (17.1) | 13 | (14.0) | ||||
> 45 | 28 | (68.3) | 76 | (81.7) | ||||
CrCl (mL/min) | 0.124a) | |||||||
< 30 | 8 | (19.5) | 7 | (7.5) | ||||
30–50 | 13 | (31.7) | 36 | (38.7) | ||||
> 50 | 20 | (48.8) | 50 | (53.8) | ||||
Creatinine kinase > 230 (IU/L) | 8 | (20.0) | 23 | (24.7) | 0.554a) | |||
C-reactive protein > 0.3 (mg/L) | 21 | (56.8) | 40 | (50.0) | 0.496a) | |||
BNP ≥ 100 (pg/mL) | 28 | (73.7) | 65 | (74.7) | 0.904a) | |||
PT-INR ≥ 1.6 | 4 | (10.3) | 9 | (10.8) | 1.000b) | |||
HbA1c ≥ 6.5 (NGSP %) | 13 | (34.2) | 15 | (22.4) | 0.188a) | |||
HDL-cho < 40 (mg/dL) | 9 | (23.7) | 15 | (18.1) | 0.472a) | |||
LDL-cho ≥ 120 (mg/dL) | 7 | (18.9) | 21 | (26.3) | 0.387a) | |||
Triglyceride ≥ 150 (mg/dL) | 6 | (15.8) | 10 | (12.5) | 0.626a) | |||
EF < 40 (%) | 9 | (23.1) | 21 | (23.1) | 1.000a) |